Dr. Lang Lin, MD

Dr. Lin practices at Morton Plant Hospital in Clearwater, Florida, part of BayCare Health System.

Dr. Lin's NPI, 1497717409, was assigned on April 5, 2006. Dr. Lin graduated from Shanghai Medical University in 1984. Dr. Lin holds Florida license ME69521.

Dr. Lin's primary practice is Morton Plant Hospital, at 300 Pinellas St, Clearwater, FL 33756 in Pinellas County. The practice phone is (727) 462-7000.

Dr. Lin's primary practice is Morton Plant Hospital in Clearwater, Florida, part of BayCare Health System. Dr. Lin is also affiliated with BayCare Mease Countryside Hospital. The medical group on file is BayCare Medical Group. Dmand AI also links Dr. Lin to 2 more hospitals, 5 group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 9 sites in all. Vendor and product names are available with a free account.

Interventional cardiology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207RI0011X. Dr. Lin is board certified in cardiovascular disease by the American Board of Internal Medicine. Dr. Lin is licensed in Florida.

Dmand AI lists angioplasty and cardiac catheterization among the conditions Dr. Lin treats.

CMS data shows 1,552 Medicare services from Dr. Lin across 18 procedure codes in 2024, for 918 Medicare patients. Medicare paid $124,145 for them.

CMS counts 918 Medicare patients who saw Dr. Lin in 2024. The largest group is 75 to 84, with 357 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 74, with 44% women.

In 2024, Dr. Lin wrote 1,889 Medicare Part D claims for 304 patients. 82% of them were for generic drugs. CMS names the drug for 1,708 of them, across 32 drugs with 11 or more claims each, at $377,103 in total drug cost. In 2023, CMS named 1,717 claims across 34 drugs.

Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 42 procedures of coronary angioplasty and stenting by Dr. Lin, more than 78% of the clinicians it reports for that procedure.

Pacemaker insertion or repair: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 5 papers to Dr. Lin, published from 2020 to 2025. The most frequent topics are Aortic Valve, Aortic Valve Stenosis and Heart Valve Prosthesis. Dr. Lin's most frequent co-authors are Hemal G. Gada, MD, Blake Isaac Gardner, MD and Kendra Janel Grubb, MD.

Dmand AI links Dr. Lin to 8 clinical trials. 6 are still active or recruiting. Conditions studied include Ventricular Outflow Obstruction, Aortic Valve Stenosis and Hemorrhagic Stroke. Medtronic Cardiovascular sponsors the most, 4.

CMS Open Payments shows 496 general payments to Dr. Lin from 36 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 35% of the total. Boston Scientific Corporation paid the most, $29,440. It also lists 2 research payments totaling $74 in 2023.

Dmand AI lists 2 awards for Dr. Lin, most recently CMS Stage 1 2012 in 2011.

Dr. Lin graduated from Shanghai Medical University in 1984. Dr. Lin is a member of ACC.

Dr. Lin is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.